Earnings ·
Femasys Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update highlighting…
FEMYFemasys Inc
Femasys Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update highlighting key strategic milestones. The company completed a $30 million private placement with potential proceeds of up to $90 million upon full warrant exercise, which management states provides capital to execute its U.S. commercial strategy and advance clinical programs. Femasys regained compliance with Nasdaq listing requirements and appointed John Canning as Chief Operating Officer. For the quarter ended June 30, sales decreased 18.9% to $331,827 from $409,268 in the prior year period, while R&D expenses increased 37.6% to $1,946,878 due to higher clinical costs and inventory transitions. The net loss for the quarter was $4,469,095, or ($1.33) per share, compared to a net loss of $4,585,922 in the same period last year. Cash and cash equivalents stood at approximately $1.4 million as of June 30, 2026. Femasys Inc. is a biomedical innovator developing fertility treatments and non-surgical permanent birth control solutions.